UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 6, 2023

TREVENA, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

955 Chesterbrook Boulevard, Suite 110

Chesterbrook, PA 19087

(Address of principal executive offices and zip code) 

Registrant’s telephone number, including area code: (610) 354-8840

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On September 6, 2023, Trevena, Inc. (the “Company”) updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached hereto as Exhibit 99.1.  

Also on September 6, 2023, the Company updated its website to include a revised TRV045 overview deck. A copy of the TRV045 overview deck is attached hereto as Exhibit 99.2.  

The information set forth on this Item 7.01 and furnished hereto as Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.  

On September 6, 2023, Trevena, Inc. (the “Company”) issued two press releases. The first press release announced new preliminary data from the two Phase 1 proof-of-concept studies of TRV045. TRV045 is a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1. The first study was the Target Engagement (PainCart®) proof-of-concept study, and the second study was the TMS proof-of-concept study. A copy of the first press release with more detail about both studies is furnished hereto as Exhibit 99.3 and incorporated herein by reference.

The Company’s second press release announced, among other things, receipt of the $15 million tranche from its non-dilutive financing with R-Bridge Investment Four Pte. Ltd., an affiliate of CBC Group, as well as other general business updates. A copy of the second press release is furnished hereto as Exhibit 99.4 and incorporated herein by reference.

The information set forth in this Item 8.01 and furnished hereto as Exhibit 99.3 and 99.4 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.